We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

Single-Tube Multimarker Assay Estimates Preeclampsia Risk

By LabMedica International staff writers
Posted on 03 Dec 2020
Print article
Image: The Luminex MAGPIX Instrument System (Photo courtesy of Thermo Fisher Scientific).
Image: The Luminex MAGPIX Instrument System (Photo courtesy of Thermo Fisher Scientific).
The challenge in the clinical practice of pregnancy monitoring is to distinguish isolated gestational hypertension or proteinuria from the development of preeclampsia (PE) with potential severe consequences to the mother and unborn child.

PE is considered a disease of placenta, caused by defective placental formation and/or its impaired functional capacity. The molecules secreted by placenta and released to the maternal blood stream have been the most popular candidates of noninvasive biomarkers for PE prognosis.

Biomedical Scientists at the University of Tartu (Tartu, Estonia) recruited both pregnant women and a subgroup of healthy non-pregnant women. The study included 53 spontaneously conceived single pregnancy cases representing alternative gestational curricula with respect to the development of PE. During the index pregnancy, 22 women had eventually developed PE (age 28.0 ± 5.2 years; nulliparity 77%; male newborn 54.5%) and 31 gestations proceeded until delivery without PE (aged 28.5 ± 5.1 years; nulliparity 51.6%; male newborn 48.4%).

The team developed and used the Luminex xMAP based assay (Luminex Corporation, Austin TX, USA) that was targeted to previously established maternal serum biomarkers for PE prediction: Soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), soluble endoglin (sENG), leptin, disintegrin and metalloproteinase domain-containing protein 12 (ADAM12), adiponectin, and Pentraxin 3 (PTX3). The B•R•A•H•M•S Kryptor sFlt-1/PlGF test (Thermo Fisher Scientific, Hennigsdorf, Germany) was applied as an external reference. Alternative PE prediction formulae combining 6PLEX measurements with clinical parameters were developed.

The scientists reported there was a high correlation in sFlt-1/PlGF estimated for individual sera between the 6PLEX and B·R·A·H·M·S Kryptor immunoassays. The predictive power of the 6PLEX combined with gestational age and maternal weight at sampling reached AUC 0.99 with sensitivity 100.0% and specificity 96.9%. In all models, sFlt-1/PlGF derived from the B·R·A·H·M·S immunoassays exhibited the lowest AUC value (<0.87) and sensitivity (<80%) with broad confidence intervals (13%–92%). The estimated prognostic yield of the 6PLEX compared to the B·R·A·H·M·S assay was significantly higher (96.5% versus 73.7%).

The authors concluded that the developed single-tube multimarker assay for PE risk estimation in combination with clinical symptoms reached high prognostic yield (96.5%) and exhibited superior performance compared to the sFlt-1/PlGF test. The study was published in the November, 2020 issue of The Journal of Applied Laboratory Medicine.

Gold Supplier
SARS-CoV-2 (COVID-19) Antibody Test
Silver Supplier
SARS-CoV-2 Antibody Test
EliA SARS-CoV-2-Sp1 IgG test
Gold Supplier
Tumor Marker Control
Tumor Marker Control

Print article


Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more


view channel

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.